CNW Group

CNW Group: "NeuroMedix Inc. ('NeuroMedix') (TSXV: NMX) today announced that it has completed maximum tolerated dose ('MTD') studies in two species of animals for Minozac, its lead drug candidate for the treatment of Alzheimer's disease. The MTD studies were completed in two species of animal and have defined the MTD of the compound based on oral dosing to be in excess of 40 times the therapeutic dose used in a mouse model of Alzheimer's disease. The results demonstrate that Minozac has no obvious side-effects that might limit its therapeutic use in human patients. The MTD results will be used to select a starting dose for longer-term 28-day repeat dose studies as well as in additional safety pharmacology studies."